Update on NMOSD & MOGAD programme
The two-day Update on NMOSD and MOGAD meeting offers an in-depth exploration of the latest advancements in these fields.
Day 1 will be dedicated to a comprehensive update on NMOSD and MOGAD, covering advances in diagnosis, differential diagnosis, prognosis, and imaging, as well as current and emerging treatment strategies. Expert-led sessions will address antibody testing, recent revisions to the McDonald criteria, acute and preventive therapies, symptomatic management, and practical clinical decision-making, complemented by case-based discussions and a keynote lecture.
Day 2 will focus on scientific exchange and future perspectives, featuring a keynote lecture, oral communications on both clinical and basic research, poster sessions, and industry-led symposia. The programme will conclude with dedicated sessions on NMOSD and MOGAD research in Asia, offering important regional insights and fostering international collaboration.
The meeting will be accessible both onsite and online, allowing broad international participation.
The programme follows the Japanese Standard Time zone: (UTC/GMT +09:00)
Download the full programme here!
| Hour Location |
Title | Location |
|---|---|---|
|
9:45-10:00 |
Opening Ceremony Hans-Peter Hartung Dr. Kazuo Fujihara Dr. Ichiro Nakashima Jacqueline Palace |
|
|
10:00-11:40 |
Session 1: Diagnosis, differential diagnosis and prognosis of NMOSD and MOGAD Dr. Takashi Ohashi Dr. Norio Chihara Dr. Tomoko Okamoto |
|
| 10:00-10:30 |
Clinical and prognostic features of NMOSD Dr. Ho Jin Kim |
|
| 10:30-10:50 |
Clinical and prognostic features of MOGAD Dr. Lekha Pandit |
|
| 10:50-11:20 |
MRI and other Imaging findings Dr. Friedemann Paul |
|
| 11:20-11:40 |
Evoked potentials & OCT Letizia Leocani |
|
|
11:40-12:00 |
Coffee Break |
|
|
12:00-13:00 |
Industry Symposium: Chugai - lunch box offered Dr. Kazuo Fujihara |
|
| 12:00-12:30 |
Updates on the clinicopathological mechanism of MOGAD Dr Tatsuro Misu |
|
| 12:30-13:00 |
Modifying Immune Cells for Neuroprotection: Lessons from Neuromyelitis Optica Dr. Norio Chihara |
|
|
13:15-14:15 |
Session 2: Antibody assays and the 2024 McDonald Criteria Dr. Jin Nakahara Dr. Kazumasa Yokoyama Dr. Makoto Kinoshita |
|
| 13:15-13:45 |
Antibody assays and how to use them in diagnosis and monitoring Jacqueline Palace |
|
| 13:45-14:15 |
The 2024 Revisions to McDonald Criteria of MS, implications on differential diagnosis with NMOSD and MOGAD Hans-Peter Hartung |
|
|
14:35-16:15 |
Session 3: Treatment of NMOSD and MOGAD Dr. Hirofumi Ochi Dr. Hiroaki Yokote Dr. Katsuhisa Masaki |
|
| 14:35-15:05 |
Treatments for acute exacerbation: when and how? Dr. Sasitorn Siritho |
|
| 15:05-15:25 |
Symptomatic therapy to improve QOL Jefferson Becker |
|
| 15:25-15:55 |
Conventional immunosuppressive treatments for relapse prevention Dr. Ichiro Nakashima |
|
| 15:55-16:15 |
Monoclonal antibodies and new and future treatments including CAR-T Therapy Dr. Romain Marignier |
|
|
16:15-16:35 |
Coffee Break |
|
|
16:35-17.25 |
Session 4: General discussion on treatment, Pregnancy-related issues and Tolerance induction Dr. Noriko Isobe Dr. Nobuaki Yoshikura Dr. Satoru Oji |
|
| 16:35-16:55 |
General Discussion: How should we use currently available treatments in clinical practice? Dr. Ho Jin Kim Dr. Ichiro Nakashima Jacqueline Palace Dr. Friedemann Paul Dr. Sasitorn Siritho |
|
| 16:55-17:25 |
Pregnancy-related issues in NMOSD and MOGAD Dr. Yuko Shimizu |
|
|
17:25-17:45 |
Guthy-Jackson Lecture |
|
| 17:25-17:45 |
Challenges in inducing tolerance in NMOSD and MOGAD Dr. Michael Yeaman |
|
|
18:30-20:30 Hotel Kizankan, Tokyo |
Gala Dinner - Sponsored by The Sumaira Foundation |
Hotel Kizankan, Tokyo |
| Hour Location |
Title | Location |
|---|---|---|
|
09:30-10:00 |
Key Note Lecture Dr. Tatsusada Okuno Dr. Fumitaka Shimizu Dr. Kazuhide Ochi |
|
| 09:30-10:00 |
AQP4 autoimmunity and immunopathogenesis in NMOSD Dr. Takashi Yamamura |
|
|
10:00-11:00 |
Session 5 : Oral Communications - Young Investigators Dr. Katsuichi Miyamoto Dr. Juichi Fujimori Dr. Chiyoko Nohara |
|
| 10:00-10:15 |
Distinct Contributions of Brain Volume and Myelin to Cognitive Function in MS and NMOSD: A Synthetic MRI Study Dr. Keito Ishihara |
|
| 10:15-10:30 |
Assessment of germline and somatic mutations contributing to the risk of neuromyelitis optica spectrum disorder Dr. Tomohiro Yata |
|
| 10:30-10:45 |
Re-evaluation of the components of IPMOGAD criteria in CNS inflammatory diseases Dr. Naoki Yamamoto |
|
| 10:45-11:00 |
Altered monocyte dynamics and C5a-associated plasmablast expansion in AQP4+ neuromyelitis optica Dr. Yuriko Aratake |
|
|
11:00-11:20 |
Coffee Break |
|
|
11:20-12:20 Exhibition Hall |
Poster Session - Sponsored by UCB |
Exhibition Hall |
| 11:20-12:20 |
Clinical 1 Jacqueline Palace Dr. Sasitorn Siritho Dr. Kazumasa Okada |
|
| 11:20-12:20 |
Clinical 2 Hans-Peter Hartung Dr. Ho Jin Kim Dr. Ichiro Nakashima |
|
| 11:20-12:20 |
Clinical 3 & Basic Studies Dr. Paul Friedemann Dr. Noriko Isobe Dr. Makoto Kinoshita |
|
|
12:20-12:50 |
Industry Lecture: Tanabe - lunch box offered Dr. Jin Nakahara |
|
| 12:20-12:50 |
B-cells in the pathogenesis of NMOSD Dr. Koji Shinoda |
|
|
13:00-14:00 |
Session 6: Oral Communications - Investigators Dr. Hiroyuki Takeuchi Dr. Takuya Matsushita Dr. Takayuki Kondo |
|
| 13:00-13:15 |
Neutrophil activation imprints type 1 interferon signature in NMOSD Dr. Hisashi Murata |
|
| 13-15:13.30 |
Increase in Cytotoxic Eomes-Expressing Helper T cells Associated with Refractory Neuromyelitis Optica Dr. Eiichiro Amano |
|
| 13:30-13:45 |
Real-World Use of Anti-CD19 (Inebilizumab)-Mediated Deep B-Cell Depletion in AQP4-IgG+ NMOSD: German NEMOS Cohort Results Dr. Orhan Aktas |
|
| 13:45-14:00 |
Distinct Microstructural White Matter Alterations in Demyelinating Diseases: Insights from Myelin- and Axon-Sensitive MRI Dr. Yasunobu Hoshino |
|
|
14:00-15:00 |
Industry Symposium: Alexion Dr. Jin Nakahara |
|
| 14:00-14:30 |
Complement Inhibition for Precision Treatment of AQP4-Ab+ NMOSD Dr. Jin Nakahara |
|
| 14:30-15:00 |
Re-evaluating AQP4-Ab+ NMOSD via Advanced Imaging Dr. Darin Okuda |
|
|
15:00-16:20 |
Session 7: NMOSD and MOGAD Research in Asia Dr. Masaaki Niino Dr. Masahiro Mori Dr. Yuji Tomizawa |
|
| 15:00-15:20 |
Anti-CD38 daratumuamab in NMOSD: the final outcomes of a phase III, double blind, randomized, multi-centre, placebo-control, DAWN trial Fu-Dong Shi |
|
| 15:20-15:50 |
Immunopathology of NMOSD Dr. Izumi Kawachi |
|
| 15:50-16:20 |
Immunopathology of MOGAD Dr Yoshiki Takai |
|
|
16:20-16:35 |
Closing Ceremony Hans-Peter Hartung Dr. Kazuo Fujihara Dr. Ichiro Nakashima Dr. Paul Friedemann |